Artivion started at market outperform by JMP, stent graft devices cited

seekingalpha10-24

JMP has initiated coverage of Artivion (NYSE:AORT) at market outperform, citing the company’s aortic-centric solutions, which include valve replacements and stent grafts. The investment firm said it ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477255728?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/915523904/image_915523904.jpg","is_english":true,"pubTime":"2024-10-24 01:45","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2477255728","market":"sg","top_or_hot":-1,"title":"Artivion started at market outperform by JMP, stent graft devices cited","media":"seekingalpha","content":"<div>\n<p>JMP has initiated coverage of Artivion (NYSE:AORT) at market outperform, citing the company’s aortic-centric solutions, which include valve replacements and stent grafts. The investment firm said it ...</p>\n\n<a href=\"https://seekingalpha.com/news/4196721-artivion-started-at-market-outperform-by-jmp-stent-graft-devices-cited\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artivion started at market outperform by JMP, stent graft devices cited</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtivion started at market outperform by JMP, stent graft devices cited\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-24 01:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4196721-artivion-started-at-market-outperform-by-jmp-stent-graft-devices-cited><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JMP has initiated coverage of Artivion (NYSE:AORT) at market outperform, citing the company’s aortic-centric solutions, which include valve replacements and stent grafts. The investment firm said it ...</p>\n\n<a href=\"https://seekingalpha.com/news/4196721-artivion-started-at-market-outperform-by-jmp-stent-graft-devices-cited\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AORT","symbol_name":"Artivion","start_time":0,"source_url":"https://seekingalpha.com/news/4196721-artivion-started-at-market-outperform-by-jmp-stent-graft-devices-cited","article_id":"2477255728","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/915523904/image_915523904.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477255728","pubTimestamp":1729705549,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"JMP has initiated coverage of Artivion  at market outperform, citing the company’s aortic-centric solutions, which include valve replacements and stent grafts. The investment firm said it views Artivion as a “unique small cap name worth owning, given its dependable base business, complementary advanced stent graft division, EBITDA growth and margin profile, and potential upside from notable shots on goal slated for the years ahead.”  JMP said that while the stock is up around 50% year-to-date, the price still doesn’t “fully capture the potential upside from the possible FDA PMA approvals within its advanced stent graft business.” The investment firm set a price target of $33 for the stock.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"AORT":"Artivion"},"translate_title":"JMP引用了Artivion的市场表现，支架移植器械","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":0.9},"content_text":"JMP has initiated coverage of Artivion (NYSE:AORT) at market outperform, citing the company’s aortic-centric solutions, which include valve replacements and stent grafts. The investment firm said it views Artivion as a “unique small cap name worth owning, given its dependable base business, complementary advanced stent graft division, EBITDA growth and margin profile, and potential upside from notable shots on goal slated for the years ahead.”  JMP said that while the stock is up around 50% year-to-date, the price still doesn’t “fully capture the potential upside from the possible FDA PMA approvals within its advanced stent graft business.” The investment firm set a price target of $33 for the stock.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477255728"}